WSGR logoWSGR logo
August Li
Patent Agent
Patents and Innovations
Washington, D.C.

D202-973-8884

Download vCard
Open PDF

T. August Li is a patent agent in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations practice. With extensive interdisciplinary research experience in molecular and clinical pharmacology, and additional focuses in glycobiology, neuroscience, and immunology, August assists clients in preparation and prosecution of patent applications.

Prior to joining the firm, August trained under Dr. Ronald Schnaar at the Johns Hopkins University, where she discovered anti-inflammatory proteoglycans that engage human Siglecs in the esophagus, airways, and brain. She also has studied the roles of gangliosides in glutamate receptor trafficking to understand the seizures and learning disabilities seen in patients with congenital disorders of ganglioside biosynthesis. Her technical expertise spans molecular biology, cell biology, biochemistry, and glycobiology. August obtained her Doctor of Pharmacy at Purdue University, where she gained profound knowledge of pathophysiology, pharmacotherapy, and drug development. 

Experience

T. August Li is a patent agent in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations practice. With extensive interdisciplinary research experience in molecular and clinical pharmacology, and additional focuses in glycobiology, neuroscience, and immunology, August assists clients in preparation and prosecution of patent applications.

Prior to joining the firm, August trained under Dr. Ronald Schnaar at the Johns Hopkins University, where she discovered anti-inflammatory proteoglycans that engage human Siglecs in the esophagus, airways, and brain. She also has studied the roles of gangliosides in glutamate receptor trafficking to understand the seizures and learning disabilities seen in patients with congenital disorders of ganglioside biosynthesis. Her technical expertise spans molecular biology, cell biology, biochemistry, and glycobiology. August obtained her Doctor of Pharmacy at Purdue University, where she gained profound knowledge of pathophysiology, pharmacotherapy, and drug development. 

Focus Areas
Recent Insights
Client Highlights
Wilson Sonsini Advises Opus Genetics on IP Matters Related to Acquisition by Ocuphire Pharma
On October 22, 2024, Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of patients with retinal and refractive eye disorders, announced the all-stock acquisition of Opus Genetics, Inc., a clinical-stage gene therapy company for inherited retinal diseases (IRDs). The merger creates a transformative biotech company committed to being a leader in the development of gene therapies for the treatment of IRDs. In connection with the merger, the combined company will be renamed Opus Genetics, Inc., effective October 23, 2024, and will trade on Nasdaq under the ticker symbol “IRD” effective October 24, 2024.
Learn More
WSGR logo
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.